MedTrace Logo

EXoPERT EMERALD Clinical Study

NCT07186296 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2026-07-01

No results posted yet for this study

Summary

The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.

Conditions

Interventions

DIAGNOSTIC_TEST

EXoPred

Performing invitro Diagnostics with devices developed by EXoPERT.

Sponsors & Collaborators

  • MCRA

    collaborator INDUSTRY

  • EXoPERT

    lead INDUSTRY

Principal Investigators

  • Jonathan Dudley, MD · Johns Hopkins University

  • Saeed Jortani, Ph.D. · Kentucky Clinical Trial Laboratory

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-09
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07186296 on ClinicalTrials.gov